Scarica l'app Stockscreener
355.20
0.32%
1.14
Dopo l'orario di chiusura:
355.98
0.78
+0.22%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$354.06
Aprire:
$357.395
Volume 24 ore:
2.73M
Relative Volume:
1.04
Capitalizzazione di mercato:
$191.70B
Reddito:
$37.30B
Utile/perdita netta:
$7.80B
Rapporto P/E:
24.70
EPS:
14.3793
Flusso di cassa netto:
$8.60B
1 W Prestazione:
+1.61%
1M Prestazione:
+5.62%
6M Prestazione:
+11.79%
1 anno Prestazione:
+19.48%
Intervallo 1D:
$351.96
$358.17
Intervallo di 1 settimana:
$337.49
$358.46
Portata 52W:
$267.83
$391.29
Amgen Inc Stock (AMGN) Company Profile
Nome
Amgen Inc
Settore
Industria
Telefono
(805)447-1000
Indirizzo
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
355.20 | 191.70B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,133.00 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
240.87 | 579.83B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
227.73 | 402.35B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
119.05 | 294.03B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.07 | 292.07B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-21 | Iniziato | Canaccord Genuity | Hold |
| 2026-03-10 | Iniziato | Jefferies | Hold |
| 2026-02-20 | Iniziato | Barclays | Equal Weight |
| 2026-01-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-12-05 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-11-24 | Ripresa | Truist | Hold |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-09-03 | Ripresa | Raymond James | Mkt Perform |
| 2025-05-20 | Ripresa | Guggenheim | Neutral |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-14 | Downgrade | Truist | Buy → Hold |
| 2024-09-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2024-05-03 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-02 | Aggiornamento | Truist | Hold → Buy |
| 2023-10-20 | Ripresa | JP Morgan | Neutral |
| 2023-10-17 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-10-11 | Ripresa | BofA Securities | Neutral |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-04-24 | Reiterato | Oppenheimer | Outperform |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | Reiterato | Truist | Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Underperform |
| 2022-10-31 | Downgrade | Barclays | Equal Weight → Underweight |
| 2022-10-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-09 | Reiterato | Barclays | Equal Weight |
| 2022-02-09 | Reiterato | Jefferies | Buy |
| 2022-02-09 | Reiterato | Morgan Stanley | Equal-Weight |
| 2022-02-09 | Reiterato | Oppenheimer | Outperform |
| 2022-02-09 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-09-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | Iniziato | Daiwa Securities | Buy |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | Aggiornamento | Truist | Hold → Buy |
| 2020-10-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | Downgrade | Truist | Buy → Hold |
| 2020-10-08 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | Ripresa | Guggenheim | Neutral |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-03-30 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-17 | Ripresa | Morgan Stanley | Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-11-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-08-19 | Downgrade | Mizuho | Buy → Neutral |
| 2019-05-23 | Aggiornamento | Citigroup | Neutral → Buy |
Mostra tutto
Amgen Inc Borsa (AMGN) Ultime notizie
Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape - PR Newswire
Healthcare of Ontario Pension Plan Trust Fund Sells 64,867 Shares of Amgen Inc. $AMGN - MarketBeat
Atlas Capital Advisors Inc. Takes $2.20 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Stock Valuation Looks Split Between Analyst Targets And DCF Upside - simplywall.st
Morgan Stanley Raises Amgen (AMGN) Price Target Following a Strong Start for Uplizna - Insider Monkey
Wall Street Zen Upgrades Amgen (NASDAQ:AMGN) to Buy - MarketBeat
Amgen Inc. Stock (US0311621009): Biotech heavyweight in focus as investors weigh valuation and pipel - AD HOC NEWS
Victory Capital Management Inc. Grows Holdings in Amgen Inc. $AMGN - MarketBeat
State Street Corp Has $10.01 Billion Stock Position in Amgen Inc. $AMGN - MarketBeat
Van ECK Associates Corp Lowers Position in Amgen Inc. $AMGN - MarketBeat
Is Amgen Still Reasonable After Its Strong Run? - Kalkine Media
Here’s Why Amgen (AMGN) is Among the 7 Best Longevity Stocks to Buy Now - Insider Monkey
Korea Investment CORP Trims Stake in Amgen Inc. $AMGN - MarketBeat
Operating expenses (excl. COGS) of Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs – BCBA:AMGN.CI - TradingView
Rhenman & Partners Asset Management AB Acquires Shares of 36,000 Amgen Inc. $AMGN - MarketBeat
First National Bank of Omaha Boosts Position in Amgen Inc. $AMGN - MarketBeat
Amgen taps research firm to reassess Tavneos data - Reuters
Amgen (AMGN) Stock After Horizon Deal And Strong Multi‑Year Gains Is Price Still Reasonable - simplywall.st
Jury Tells Amgen To Pay $20.2M In Antibody Patent Trial - Law360
Amgen owes $20.2 million in antibody patent lawsuit, US jury says - marketscreener.com
Amgen Turns to an Independent Review to Defend Rare Disease Drug in FDA Crosshairs - MedCity News
Amgen owes $20.2 mln in antibody patent lawsuit, US jury says - TradingView
Amgen Seeks FDA Hearing To Challenge Proposed Tavneos Withdrawal - Benzinga
Amgen Seeks FDA Hearing To Challenge Proposed Tavneos Withdrawal - Benzinga
Amgen’s ABP 938 Takes Aim at EYLEA HD in High-Stakes Eye Disease Trial - TipRanks
Amgen Defends Tavneos Amid FDA Withdrawal Proposal - GuruFocus
Cash from investing activities of Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs – BCBA:AMGN.CI - TradingView
Piper Sandler reiterates Amgen stock rating on Sjogren’s drug - Investing.com
Piper Sandler reiterates Amgen stock rating on Sjogren’s drug By Investing.com - Investing.com Canada
Amgen's $500 Million Tavneos Faces FDA Withdrawal Fight - GuruFocus
(AMGN) Risk Channels and Responsive Allocation - Stock Traders Daily
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $427 - Moomoo
Amgen Inc. $AMGN Position Reduced by Vaughan David Investments LLC IL - MarketBeat
Swiss National Bank Has $482.87 Million Holdings in Amgen Inc. $AMGN - MarketBeat
ICICI Prudential Asset Management Co Ltd Has $8.87 Million Stake in Amgen Inc. $AMGN - MarketBeat
9,812 Shares in Amgen Inc. $AMGN Bought by Meiji Yasuda America Inc - MarketBeat
Nuveen LLC Sells 86,287 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. Stock (US0311621009): Shares Jump On EU Cancer Drug Approval And New Trial Data - AD HOC NEWS
Amgen Inc. Stock (US0311621009): Dow component under pressure after recent pullback - AD HOC NEWS
Aviva PLC Purchases 23,465 Shares of Amgen Inc. $AMGN - MarketBeat
A Look at Amgen Inc (AMGN) After 4.8% Gain -- GF Value $353.35 vs Price $354.06 - GuruFocus
Amgen (AMGN) Faces FDA Scrutiny Over Tavneos Amid Safety Concerns - GuruFocus
Amgen Reevaluates Tavneos Data as Drug Faces FDA Scrutiny - Bloomberg
A Look at Amgen Inc (AMGN) After 4.8% Gain -- GF Value $353.35 v - GuruFocus
Amgen hires Duke research organization to save Tavneos from market removal - Seeking Alpha
Amgen taps Duke Research Institute to reevaluate disputed Tavneos data - Investing.com
Amgen taps Duke Research Institute to reevaluate disputed Tavneos data By Investing.com - Investing.com Canada
Amgen’s Repatha Diabetes Data Reframes Cardiometabolic Upside For Investors - simplywall.st
Amgen Inc. (AMGN) is attracting investor attention: Here is what you should know - MSN
Amgen Reevaluates Tavneos Data as Medicine Faces FDA Scrutiny - Bloomberg.com
Amgen Hires Avenue Solutions for Medicare Lobbying - Legis1
Amgen Inc Azioni (AMGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.18%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):